Fresh financial data from QuidelOrtho reveals ongoing challenges, including constant currency revenue declines and pressured cash flow, forcing investors to weigh the stock's risk-reward profile as its momentum appears to fade.
At CES 2026, Qualcomm and ECARX unveiled the Snapdragon Elite-powered Zenith computing platform, marking a significant escalation in the chipmaker's push to capture the high-value automotive AI market and diversify beyond its smartphone roots.
Nvidia CEO Jensen Huang has publicly committed to a landmark investment in OpenAI, calling it potentially the company's largest ever, while forcefully refuting reports of hesitation. The move deepens the strategic ties between the AI chip giant and the leading AI research lab.
Polish military police are investigating after a small, commercially available drone of unknown origin crashed inside a sensitive army facility in Przasnysz, highlighting persistent vulnerabilities in European airspace security.
Aerospace giant Boeing is joining a major U.S. public-private initiative to build a national stockpile of critical minerals, a strategic move aimed at reducing dependence on foreign sources and bolstering domestic manufacturing resilience for defense and commercial programs.
Qualcomm shares have retreated over 12% this year, prompting a fresh debate on whether the chipmaker's long-term AI and edge computing narrative justifies its current valuation.
Spanish healthtech startup Biorce has closed a substantial Series A round, backed by prominent venture capital and angel investors, to scale its AI-driven clinical trial solution, Aika, internationally amid a tightening regulatory landscape.
Life sciences and diagnostics firm Revvity (RVTY) closed 2025 with results surpassing internal targets, driven by robust diagnostics performance. While management provided initial 2026 guidance, it remains conservative, banking on market stabilization rather than a broad recovery.
Aptiv capped off 2025 with record fourth-quarter sales and detailed a transformative 2026 outlook, headlined by the imminent spin-off of its Electrical Distribution Systems unit into VersaGen. The automotive tech leader is navigating currency headwinds and strategic investments to expand beyond traditional auto markets.
The so-called 'Super Bowl Indicator' correctly predicted a market rise after last year's NFC win, but a deeper look at the data reveals it's little more than a coin toss—and a cautionary tale about spurious correlations in finance.
After a decade of development and multiple clinical setbacks, Sanofi's venglustat has met its primary goal in a Phase 3 trial for Type 3 Gaucher disease, offering new hope for neurological symptoms. The drug, however, failed a separate late-stage study for Fabry disease.
AIGH Capital Management has liquidated its entire position in semiconductor firm MaxLinear, a move that coincides with the chipmaker's recent strong quarterly earnings report, raising questions about the fund's strategy.
With one in twelve salaried employees having worked in multiple countries, Colgate-Palmolive is leveraging international assignments as a core strategy to build agile, globally-minded leadership.
Two French infant formula makers have recalled multiple product batches following the government's decision to slash permissible levels of cereulide, a toxin linked to gastrointestinal illness. The move amplifies a global safety crisis that has seen major brands issue recalls across dozens of countries since late last year.
With the FIFA World Cup in North America, the Milano Cortina Winter Olympics, and a packed calendar of major events, 2026 is poised to be a landmark year for sports. Brands and retailers are deploying sophisticated strategies that prioritize cultural marketing and community engagement over mere sales spikes, navigating a landscape where consumer loyalty is won through storytelling, not just sponsorship.
Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
H.C. Wainwright and Chardan Capital upgrade Korro Bio (KRRO) to Buy, citing the independent potential of its RNA-editing asset KRRO-121 and strong preclinical data as key catalysts.
Ardelyx, Inc. (NASDAQ: ARDX) has received significant analyst upgrades, with TD Cowen and Jefferies raising price targets ahead of the company's fourth-quarter results. The optimism centers on the commercial trajectory of its flagship drug, tenapanor, for gastrointestinal and kidney conditions.
